IL9 and asthma: Application of sialostatin L almost completely abrogates airway hyperresponsiveness and eosinophilia in a model of experimental asthma and experimental data suggest its preventing effect in this disease model (Horka et al., 2012), probably by suppressing mast cell-derived IL-9 production by inhibiting IRF4 (Klein et al., 2015).